ArticleFrontiers in pediatrics2025
Case Report: Metronidazole-induced encephalopathy in a patient with acute myeloid leukemia type 2 and a literature review of the pediatric case reports.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reversible Metronidazole-Induced Encephalopathy With Typical MRI Features Following a Low Cumulative Dose: Case Report.Clinical medicine insights. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metronidazole exerts neurotoxic effects on the central nervous system, leading to rare pediatric cases of metronidazole-induced encephalopathy (MIE). Methods: This study reports a pediatric patient with MIE. The patient's clinical and neuroimaging data was collected and analyzed. A literature review of pediatric MIE cases reported up to June 2025 was conducted using PubMed, Embase, Web of Science, Cochrane Library, WanFang, and CNKI databases. Results: A 13-year-old female developed MIE after two courses of metronidazole with cumulative doses of 31.2 g and 37.6 g. Clinical manifestations included altered mental status, ophthalmoplegia, dysarthria, dysphagia, involuntary movements, dystonia, urinary retention, muscle weakness, and absent tendon reflexes. Brain MRI revealed T2W/FLAIR and DWI hyperintensities symmetrically involving the dentate nuclei, splenium of corpus callosum, basal ganglia, thalamus, midbrain, and pons. After discontinuing metronidazole and vitamin B1 therapy, the patient's symptoms gradually improved, though extrapyramidal symptoms persisted. Repeated brain MRI at 10 days after cessation showed lesions partially resolved. Literature review identified 18 pediatric MIE cases, totaling 19 cases including our case. Except for one infant case presenting with intermittent hypothermia, bradycardia, growth retardation, reduced activity, muscle weakness and hypotonia, the predominant neurological symptoms in the other 18 cases were ataxia (11/18), altered mental status (8/18), dysarthria (7/18), and epileptic seizures (5/18). Symmetric brain MRI lesions involving dentate nuclei (13/17), splenium of corpus callosum (9/17), midbrain (6/17), pons (5/17). Most patients (17/19) achieved complete clinical resolution and brain MRI improvement after metronidazole withdrawal. Conclusion: Pediatric MIE is rare and manifests with widespread neurological involvement, characterized by cerebellar dysfunction, altered mental status, and seizures. Brain MRI typically reveals symmetrical lesions in the dentate nuclei, splenium of corpus callosum, and midbrain. Timely drug discontinuation is critical for treatment, and most cases are reversible, though a few may leave neurological sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.